secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001013762-23-003541
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees suspends Phase IIB tafenoquine COVID-19 study; pivots to malaria and babesiosis
--------------------------------------------------------------------------------

- Company will not re-submit IND for Phase IIB study (ACLR8-LR) of tafenoquine in mild-to-moderate COVID-19 after FDA feedback made U.S. enrollment unfeasible.
- Shifts focus to ARAKODA (tafenoquine) commercialization for malaria prophylaxis and preparation for Phase IIA study in hospitalized babesiosis patients.
- ARAKODA sales increased 150% in Q2 2023 vs Q2 2022; plans to appoint chief commercial officer and submit pre-IND meeting request for babesiosis in Q4 2023.
- FDA advice indicated placebo-controlled study allowed only when nirmatrelvir/ritonavir is not clinically appropriate, making patient recruitment very challenging.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000101376223003541/0001013762-23-003541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000101376223003541/ea186616-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-003541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer